|
 LSN's third Redefining Early Stage Investments (RESI) conference is fast approaching. Held twice a year, this event is the ideal place for scientist-entrepreneurs to meet early stage investors.
The idea for RESI came about while I was traveling and participating in a variety of domestic and international partnering and investor events. Considering the advertisements, I was surprised that so few qualified active investors attended many of the conferences...
|
|
By Michael Quigley, Director of Research, LSN
 As large pharmaceutical companies have cut internal R&D spending, they have established and financed venture capital branches, which have quickly become a critical source of capital for emerging life science companies. In a previous article, we discussed the two types of corporate VCs and why they can be a beneficial source of funding. This article sheds more light on corporate VCs by examining some data points from the last 50 mandates that we received from this group and by making comparisons with the rest of the investor community... |
 In the United States, the orphan disease space has gained significant interest from the investment community due to the expedited regulatory approval process, combined with the lack of current treatment options that address many of these uncommon conditions. A wide range of investor types are targeting these diseases for many different reasons. RESI brings together veterans in the orphan disease space to compare and contrast the strategies and motivations of different investors in the field.
Moderated by Peter Saltonstall, President & CEO at The National Organization for Rare Diseases (NORD), the audience will hear from:
- Mark Day, Senior Director, Strategic Evaluation, Alexion
- Jean-Marc Quach, Executive Director, The Alpha-1 Project
- Chris Adams, CEO, Cydan
- Mark Barrett, VP, Head Strategy & BD, Rare Diseases, Genzym...
|
Life Science Investor Mandates 
